Ovid Therapeutics Inc. Unveils Presentation on Innovative Neurotherapeutics Pipeline Targeting Neural Hyperexcitability Conditions

Reuters

08/15

<a href="https://laohu8.com/S/OVID">Ovid Therapeutics Inc.</a> Unveils Presentation on Innovative Neurotherapeutics Pipeline Targeting Neural Hyperexcitability Conditions

Ovid Therapeutics Inc. recently released a corporate presentation highlighting its focus on developing medicines for conditions caused by neural hyperexcitability. The company is advancing a pipeline of highly specific small molecules with differentiated mechanisms of action. Key programs include the GABA-aminotransferase inhibitor OV329 for drug-resistant adult epilepsies and developmental epileptic encephalopathies, with Phase 1 topline results expected in Q3 2025 and Phase 2a initiation in Q1 2026. The KCC2 direct activator portfolio features OV350 IV, currently in Phase 1, and OV4071 oral, aimed at psychosis associated with Parkinson's disease and Lewy body dementia, with upcoming Phase 1 trials. Ovid holds a cash balance of $38.3 million, projected to fund operations into the early second half of 2026. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief on August 14, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2559896147"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559896147\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559896147?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-15 04:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559896147","market":"us","top_or_hot":-1,"title":"Ovid Therapeutics Inc. Unveils Presentation on Innovative Neurotherapeutics Pipeline Targeting Neural Hyperexcitability Conditions","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OVID\">Ovid Therapeutics Inc.</a> Unveils Presentation on Innovative Neurotherapeutics Pipeline Targeting Neural Hyperexcitability Conditions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ovid <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. recently released a corporate presentation highlighting its focus on developing medicines for conditions caused by neural hyperexcitability. The company is advancing a pipeline of highly specific small molecules with differentiated mechanisms of action. Key programs include the GABA-aminotransferase inhibitor OV329 for drug-resistant adult epilepsies and developmental epileptic encephalopathies, with Phase 1 topline results expected in Q3 2025 and Phase 2a initiation in Q1 2026. The KCC2 direct activator portfolio features OV350 IV, currently in Phase 1, and OV4071 oral, aimed at psychosis associated with Parkinson's disease and Lewy body dementia, with upcoming Phase 1 trials. Ovid holds a cash balance of $38.3 million, projected to fund operations into the early second half of 2026. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief on August 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ovid Therapeutics Inc. Unveils Presentation on Innovative Neurotherapeutics Pipeline Targeting Neural Hyperexcitability Conditions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOvid Therapeutics Inc. Unveils Presentation on Innovative Neurotherapeutics Pipeline Targeting Neural Hyperexcitability Conditions\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-15 04:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OVID\">Ovid Therapeutics Inc.</a> Unveils Presentation on Innovative Neurotherapeutics Pipeline Targeting Neural Hyperexcitability Conditions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ovid <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. recently released a corporate presentation highlighting its focus on developing medicines for conditions caused by neural hyperexcitability. The company is advancing a pipeline of highly specific small molecules with differentiated mechanisms of action. Key programs include the GABA-aminotransferase inhibitor OV329 for drug-resistant adult epilepsies and developmental epileptic encephalopathies, with Phase 1 topline results expected in Q3 2025 and Phase 2a initiation in Q1 2026. The KCC2 direct activator portfolio features OV350 IV, currently in Phase 1, and OV4071 oral, aimed at psychosis associated with Parkinson's disease and Lewy body dementia, with upcoming Phase 1 trials. Ovid holds a cash balance of $38.3 million, projected to fund operations into the early second half of 2026. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief on August 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OVID","symbol_name":"Ovid Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nNDL8nYnKH:1","article_id":"2559896147","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559896147","pubTimestamp":1755202116,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ovid Therapeutics Inc. Unveils Presentation on Innovative Neurotherapeutics Pipeline Targeting Neural Hyperexcitability Conditions. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief on August 14, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OVID":"Ovid Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"Ovid Therapeutics Inc.推出针对神经过度兴奋状况的创新神经治疗产品线","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OVID":0.9},"content_text":"Ovid Therapeutics Inc. Unveils Presentation on Innovative Neurotherapeutics Pipeline Targeting Neural Hyperexcitability Conditions\n    \n\n        Ovid Therapeutics Inc. recently released a corporate presentation highlighting its focus on developing medicines for conditions caused by neural hyperexcitability. The company is advancing a pipeline of highly specific small molecules with differentiated mechanisms of action. Key programs include the GABA-aminotransferase inhibitor OV329 for drug-resistant adult epilepsies and developmental epileptic encephalopathies, with Phase 1 topline results expected in Q3 2025 and Phase 2a initiation in Q1 2026. The KCC2 direct activator portfolio features OV350 IV, currently in Phase 1, and OV4071 oral, aimed at psychosis associated with Parkinson's disease and Lewy body dementia, with upcoming Phase 1 trials. Ovid holds a cash balance of $38.3 million, projected to fund operations into the early second half of 2026. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief on August 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}